Nabil Dib, M.D., MSc,FACC
For more than 25 years, Dr. Dib has been conducting research and developing the newest investigational treatments for advanced cardiovascular disease. He is internationally known and respected for his research and work regarding the use of adult stem cells to restore the health of patients with severe heart disease.
Dr. Dib travels the world speaking at Cardiology events, conducting research and clinic trials and working to improve quality of life and survival for patients with cardiovascular disease.
He completed his Interventional Cardiology Fellowship Program at Harvard Medical School, Beth-Israel-Deaconess Medical Center in Boston. Dr. Dib also completed an additional year in Investigational Devices at Harvard Medical School. Additionally, he continued his education at Harvard School of Public Health, where he obtained a degree in Master of Science in Epidemiology and Research, concentrated on a clinical trial designed and effectiveness.
Dr. Dib completed three years of General Cardiology at the University of Wisconsin, Milwaukee Clinical Campus at Sinai Samaritan Medical Center. His residency was in Internal Medicine at Tufts University School of Medicine and his internship at Boston University. Dr. Dib received his Medical Degree from Damascus University School of Medicine in Damascus, Syria.
Currently, he is Director of Cardiovascular Research at Dignity Health. He is also an Associate Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy, University of California San Diego, Director of Heart Sciences Center, President and Founder of the International Society for Cardiovascular Translational Research and Editor in Chief of the Journal of Cardiovascular Translational Research.
As Director of Cardiovascular Research at Dignity Health Mercy Gilbert Regional Medical Center, Dr. Dib has led the charge for the healthcare industry to find innovative ways to utilize adult non-embryonic stem cells that may have the potential to restore the health of patients who have no other available treatments.
Dr. Dib is internationally known for his research and work with stem cell therapy. He did the first worldwide experiment to demonstrate the feasibility of stem cell transplantation using 3-D catheter guidance in February 2000 and a few months later he implanted the first patient with stem cell therapy. In 2004, he obtained the first FDA approval in the United States for stem cell transplantation for patients with heart failure and heart attack using the 3-D catheter guidance technology, a minimally invasive procedure.
Dr. Dib also authored a book on the topic titled, Stem Cell Therapy and Tissue Engineering for Cardiovascular Repair: From Basic Research to Clinical Applications.
Prior to joining Dignity Health, Dr. Dib formed Cardiovascular and Stem Cell Consultants (CSCC), a cardiology practice that provides the highest quality healthcare to patients with cardiovascular disease. CSCC also provides patients access to the newest investigational treatments for advanced cardiovascular disease such as Adult Stem Cells, Gene Therapy, and New Devices, a very important program for personalized medicine.
Additional experience includes seven years at the Arizona Heart Institute in Phoenix, Ariz., where Dr. Dib was Director of Interventional Cardiovascular Research and Director of the Interventional Fellowship Program. During his tenure with the Arizona Heart Institute, Dr. Dib was named America’s Top Doctors for Interventional Cardiology in 2003.
Throughout his career, Dr. Dib has served on several advisory boards and steering committees including: Cordis/Johnson & Johnson, Schering/Berlex, Volcano Corp., POSSIS Medical Inc., and Cardiovascular System Inc. In 2007, he was named Proctor, 3-D Mapping and stem cell transplantation for Biologics Delivery Systems/Cordis Corporation, a Johnson & Johnson Company.
He has also been involved with numerous professional affiliations such as: the American Heart Association, American College of Cardiology, American College of Physicians, International Society of Endovascular Intervention and the Massachusetts Medical Society. In addition, Dr. Dib helped write the board exam for the American College of Cardiology and is a reviewer for several medical journals and publications.
His research interests include Stem Cell Therapy for Myocardial Regeneration and Methods of Delivery, Genomics, Personalized Medicine, New Investigational Devices in Cardiology.
In addition, Dr. Dib has done extensive work in the following areas: Stent Deployment, Doppler FloWire, Pressurewire, Intravascular Ultrasound, Valvuloplasty, Rotational Atherectomy, Directional Atherectomy, Beta-Radiation, Novoste, Possis Angiojet, PercuSurge GuardWire System, Angioseal, Perclose and Vasoseal.
To learn more about Dr. Dib’s accomplishments and recent media coverage, visit our Media Center.